Arecor Inks Co-Development Deal, Sells Royalty Rights
Arecor Therapeutics has struck a co-development deal with Sequel Med Tech to pair AT278, its ultra-concentrated (500 U/mL), ultra-rapid...
eClinical Tech News
Basilea Awarded BARDA Contract for a Promising New Antibiotic
Basilea Pharmaceutica has secured a BARDA contract novation to support the development of ceftibuten–ledaborbactam etzadroxil, an investigational oral beta-lactam/beta-lactamase...
Merck’s Verona Pharma Acquisition Gets Shareholder Approval
Verona Pharma shareholders have approved Merck’s proposed acquisition of the company for $107 per American Depositary Share, valuing the...
Briumvi Data: 90% Free of MS Disability Progression at 6 Yrs
TG Therapeutics reported six-year outcomes for Briumvi (ublituximab) from the ULTIMATE I & II Phase 3 programs at ECTRIMS...
Partnership Launches New Radiopharmaceutical Trial for TNBC
Cellectar Biosciences has selected Evestia Clinical as a full-service CRO for a Phase 1b study of CLR 125 in...
Leqembi Approved for Alzheimer’s Treatment in Australia
Australia’s Therapeutic Goods Administration has approved Leqembi (lecanemab) for adults with early Alzheimer’s disease who are APOE ε4 non-carriers...
Roche Presents New Ocrevus, Fenebrutinib Data at ECTRIMS
Roche used ECTRIMS 2025 to consolidate its multiple sclerosis franchise on two fronts: durability and diversification. New data show...
Synendos’ Positive Phase 1 Results Pave Way for Phase 2
Synendos Therapeutics has reported positive topline results from a completed Phase 1 program of SYT-510, a first-in-class selective endocannabinoid...
Biogen Announces Regulatory Update on High-Dose Nusinersen
Biogen has received a Complete Response Letter from the FDA for its supplemental filing to add a high‑dose regimen...
Synendos’ Phase 1 Breakthrough in Mental Health Treatment
Synendos Therapeutics reported positive topline Phase 1 results for SYT-510, a first-in-class Selective Endocannabinoid Reuptake Inhibitor, in healthy volunteers....